Medical Disclaimer and Safety

1. What the service is for

GLPzy is designed to help users organise and review personal tracking records such as medication logs, supported medication pages, custom medication profiles, reminders, symptom entries, weight and wellness notes, nutrition entries, and related routine information.

2. What the service is not for

The service is not intended to diagnose, treat, cure, mitigate, or prevent disease. It is not intended to replace medical judgment or clinical advice. For this release, GLPzy is not offered as a regulated medical device.

3. No dosing guidance

You must not use the service to decide whether to start, stop, skip, delay, advance, increase, decrease, or otherwise change any medication, dose amount, dose timing, dosing interval, or treatment plan.

Questions about medication safety, side effects, tolerance, dose escalation, missed doses, or treatment changes should be directed to a qualified healthcare professional.

4. Charts, summaries, and estimates

The service may display summaries, reminders, trends, or other user-facing visualisations. These outputs are informational only. They are not laboratory measurements, clinical assessments, prescribing guidance, or validated treatment recommendations.

The estimated medication-level chart is a personal tracking estimate based on logged dose timing plus simplifying assumptions. It is not a serum assay and must not be used to decide whether to change medication, timing, or dose. For custom or compounded treatments, the chart is shown only when an explicit half-life has been entered for personal tracking review.

5. Non-emergency use only

The service is not an emergency service and is not monitored for urgent health events. If you believe you may be experiencing a medical emergency, seek urgent medical help immediately.

6. Accuracy of user-entered information

The usefulness of any logs, summaries, exports, or reminders depends in part on the accuracy of the information entered by the user and the technical functioning of the device, platform permissions, and any enabled integrations. Errors, omissions, platform delays, and other technical limitations may occur.

7. Approved product information and clinician instructions prevail

If there is any difference between what you see in the service and the instructions given by your clinician, pharmacist, or the relevant product labelling, you should follow the clinician or product instructions.

8. Sharing exports with clinicians

The service may allow you to export or share summaries. These exports are user-directed tools for communication and record-keeping. They do not convert the service into a clinical system, prescribing support tool, or medical advice service.

9. Methodology and assumptions

GLPzy explains the Estimated Exposure Trend feature in more detail on the Methodology and Limitations page, including what inputs are used, what assumptions are made, and what the estimate ignores.

10. References and official information

For the current public website and app release, the main supported medication pages are organised like this:

• Tirzepatide pages: Mounjaro and Zepbound, with tirzepatide as the broader ingredient page for related tracking in GLPzy.
• Semaglutide pages: Wegovy and semaglutide are the main public indexed pages. Additional noindex pages in the bundle include Ozempic and Rybelsus.
• Foundayo page: if retained, keep it separate from semaglutide and describe it as orforglipron, not semaglutide.
• Daily pen pages: Victoza, Trulicity, and Saxenda remain available in the site bundle as noindex pages.
• Flexible tracking paths: compounded and custom medication tracking remain available in the app for personal tracking, but these pages are not treated as core index targets in the public sitemap.

The same references listed below are available in the app under Settings > Medical references and from the in-context BMI and Estimated Exposure Trend source affordances.

• CDC: About Body Mass Index (BMI)
• CDC: Adult BMI Categories
• FDA: Wegovy prescribing information
• FDA: Zepbound prescribing information
• FDA: Mounjaro prescribing information
• FDA: Ozempic prescribing information
• FDA: Rybelsus prescribing information
• FDA: Saxenda prescribing information
• FDA: Victoza prescribing information
• FDA: Trulicity prescribing information
• emc: Wegovy Summary of Product Characteristics (SmPC)
• emc: Mounjaro Summary of Product Characteristics (SmPC)
• emc: Ozempic Summary of Product Characteristics (SmPC)
• emc: Rybelsus Summary of Product Characteristics (SmPC)
• emc: Saxenda Summary of Product Characteristics (SmPC)

11. Contact

For product questions, contact [email protected]. Support cannot provide clinical guidance.